Showing 7041-7050 of 7932 results for "".
- Mayo Clinic Data: Two Forms of Nonmelanoma Skin Cancer on the Risehttps://practicaldermatology.com/news/mayo-clinic-data-two-forms-of-nonmelanoma-skin-cancer-on-the-rise/2458167/Two types of non-melanoma skin cancer (NMSC) have increased significantly in recent years, according to a new report in the June 2017 issue of Mayo Clinic Proceedings. Specificall
- Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clueshttps://practicaldermatology.com/news/largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues/2458176/A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how — and why — psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Statement from AAD President Henry W. Lim, MD, FAAD, on the Safety of Sunscreenhttps://practicaldermatology.com/news/statement-from-aad-president-henry-w-lim-md-faad-on-the-safety-of-sunscreen/2458179/“The American Academy of Dermatology wants to emphasize that sunscreen remains a safe, effective form of sun protection. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cance
- SkinCeuticals Study Finds Antioxidants Protect Against Atmospheric Skin Aginghttps://practicaldermatology.com/news/skinceuticals-study-finds-antioxidants-protect-against-atmospheric-skin-aging/2458181/Exposure to ozone pollution zaps our collagen supply, according to new research from SkinCeuticals in partnership with Professor Giuseppe Valacchi from the University of Ferrara, Italy. After exposure to 0.8ppm ozone, collage
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- Study: Smiling May Not Make Us Appear Younger After Allhttps://practicaldermatology.com/news/study-smiling-may-not-make-us-appear-younger-after-all/2458186/Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to
- Valeant Appoints New Dermatology and Corporate Communications Leadership Membershttps://practicaldermatology.com/news/valeant-appoints-new-dermatology-and-corporate-communications-leadership-members/2458192/Valeant Pharmaceuticals International, Inc. added new members to the dermatology leadership team—Michael McMyne is the new Vice President of Sales and Stacey Williams is the new Vice President of Marketing. Additionally, the comp